retatrutide phase 2 obesity trial results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide hits 28% weight loss
Description
These effects are driving a spate of research into possible overlapping circuitry linking compulsive behaviors, appetite and satiety
Hormonal Research Beyond appetite and glucose regulation, GLP1-S has attracted attention for its potential effects on wider endocrine systems
Popular GLP-1 drugs include Eli Lilly's Mounjaro and Novo Nordisk's Wegovy, the latter of which has been approved by the Food and Drug Administration for weight loss management
The HCG keeps the body from going into starvation mode and holding onto fat as it resets your metabolism.
Zheng X, Xu F, Liang H, et al
What does recent research suggest about Retatrutide's potential
